Skinny Pill discontinued
This article was originally published in The Tan Sheet
Executive Summary
Fountain of Youth Group has discontinued ad claims for Skinny Pill For Kids and never actually launched the product, according to recent National Advertising Division case report. Council of Better Business Bureaus division disputed claims on Edita Kaye's 1skinny.com Web site that supplement is "the first real help in fighting fat" and is "formulated with the finest ingredients to help children reduce their risk of obesity-related diseases." In a letter to NAD, advertiser stated the claims had been "unintentionally published" on the Web site and noted that "while meetings had been held with professionals regarding development of the product, no product had been formulated." Weight-loss supplements marketed to children have received scrutiny from FTC (2"The Tan Sheet" Dec. 16, 2002, p. 5)...
You may also be interested in...
Energy & Commerce wants the skinny
Subpoena for previously requested information from Skinny Pill for Kids marketer Edita Kaye authorized June 12 by House Energy & Commerce/Subcommittee on Oversight & Investigations. Rep. James Greenwood (R-Penn.) stated Kaye and her counsel "have not provided any responsive documents or narrative responses," instead claiming that because the product was never distributed, she is not obligated to reply. Kaye made similar defense to a NAD inquiry (1"The Tan Sheet" March 31, 2003 In Brief). Committee expanded supplement probe focus beyond ephedra to include pediatric products with March 25 letter to PediaLean manufacturer (2"The Tan Sheet" April 14, 2003, p. 3)...
Weight-Loss Products For Children Could Spur Creation Of Fatter Regs – FTC
A continuing rise in the number of weight-loss supplements marketed to children could lead to "additional regulation" of weight-loss products, according to Federal Trade Commission Division of Advertising Practices Senior Staff Attorney Richard Cleland
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.